Purpose. To evaluate the presentation, management, and outcomes of patients with anal squamous cell carcinoma in a single institution. Methods. We retrospectively identified patients diagnosed as having anal squamous cell carcinoma (ASCC) between 2009 and 2019. Diagnosis coding and chart review were conducted to identify patients with a pathologically confirmed diagnosis of ASCC and obtain their data on presentation, stage, and treatment. Main outcomes were overall survival (OS) and disease-free survival (DFS). Results. A total of 18 patients (50% men; mean age: 60.8 year, range: 31- 95 years) were identified. The most common presentations were anal bleeding (58%) and anal mass sensation (42%). The tumor was located in the perianal region in 6 (33%) patients and at the anal canal (above the anal verge) in the remaining patients (66%). Furthermore, we noted early-stage (stage 0-II), stage III, and stage IV disease at diagnosis in 13, 4, and 1 patients, respectively. Among 14 (77%) patients who underwent surgery, 13 received local excision and 1 abdominal perineal resection; 12 (66%) patients received chemoradiotherapy (CRT). Among the 12 patients who received chemotherapy, 8 received cisplatin + fluorouracil as the first-line treatment. The median follow-up period was 46 months. The median OS and DFS periods were both 68 months, respectively. Conclusion. ASCC is a rare cancer, and anal bleeding and mass sensation are its most common presentations. CRT remains the main treatment for ASCC.
目的:整理並分析彰化基督教醫院的肛門鱗狀上皮癌病人的臨床表現、接受的治療以及整體的預後。.方法:我們透過回溯性的病歷收集分析了在西元2009年到西元2019年被診斷為肛門鱗狀上皮癌的病人。我們使用診斷碼來蒐集病人資料也確定每個病人都有肛門鱗狀上皮癌的病理診斷。我們記錄了各個病人的症狀、癌症分期和接受的治療。我們使用整體存活率和無病存活期來估量病人的預後。結果:總共有18個病人,平均追蹤的時間為46個月。平均年齡為60.6歲。最常見的症狀為肛門流血(58%),其次為肛門腫塊(42%)。初始癌症分期為0到2期的有14位;第三期的有3位,而第四期則有1位。有13位病人接受局部手術切除,有1位病人接受經腹部和會陰切除手術。總共有12位病人接受化學合併放射治療,其中最常用的化學藥劑為5-氟尿嘧啶加上順鉑。追蹤期間總共有4位病人復發;2個為局部復發;2個為遠端復發。追蹤期間總共有6位病人死亡;整體存活中位數為68個月,整體無病存活中位數為68個月。結論:肛門鱗狀上皮癌是一個少見的癌症,其通常是以肛門流血和肛門腫塊來表現。化療合併放射治療仍然是主要且有效的治療方式。